Alterations and Metastasis in Estrogen Receptor Positive Breast Cancer

Overview

Journal J Cancer Metastasis Treat

Date 2019 May 21

PMID 31106278

Citations 64

Authors

Jonathan T Lei

Xuxu Gou

Sinem Seker

Matthew J Ellis

Affiliations

Soon will be listed here.

Abstract

Endocrine therapy is essential for the treatment of patients with estrogen receptor positive (ER+) breast cancer, however, resistance and the development of metastatic disease is common. Understanding how ER+ breast cancer metastasizes is critical since the major cause of death in breast cancer is metastasis to distant organs. Results from many studies suggest dysregulation of the estrogen receptor alpha gene ( ) contributes to therapeutic resistance and metastatic biology. This review covers both pre-clinical and clinical evidence on the spectrum of alterations including amplification, point mutations, and genomic rearrangement events driving treatment resistance and metastatic potential of ER+ breast cancer. Importantly, we describe how these alterations may provide therapeutic opportunities to improve outcomes in patients with lethal, metastatic breast cancer.

Citing Articles

Triple-positive breast cancer: navigating heterogeneity and advancing multimodal therapies for improving patient outcomes.

Xie J, Yang Z, Li Z, Zhang T, Chen H, Chen X Cancer Cell Int. 2025; 25(1):77.

PMID: 40045297 PMC: 11881339. DOI: 10.1186/s12935-025-03680-7.

Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer.

Palaniappan M Biomedicines. 2025; 12(12.

PMID: 39767607 PMC: 11673253. DOI: 10.3390/biomedicines12122700.

Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment.

Shams A Discov Oncol. 2024; 15(1):797.

PMID: 39692941 PMC: 11655925. DOI: 10.1007/s12672-024-01701-x.

Evidence that CRISPR-Cas9 Y537S-mutant expressing breast cancer cells activate Yes-associated protein 1 to driving the conversion of normal fibroblasts into cancer-associated fibroblasts.

Gelsomino L, Caruso A, Tasan E, Leonetti A, Malivindi R, Naimo G Cell Commun Signal. 2024; 22(1):545.

PMID: 39543704 PMC: 11566413. DOI: 10.1186/s12964-024-01918-x.

Gene expression alterations in hypoxic A549 lung cancer cell line.

Abualnadi R, Tarboush N, Shhab M, Zihlif M Biomed Rep. 2024; 21(6):183.

PMID: 39420921 PMC: 11484184. DOI: 10.3892/br.2024.1871.

References

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Shoker B, Jarvis C, Sibson D, Walker C, Sloane J . Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol. 1999; 188(3):237-44. DOI: 10.1002/(SICI)1096-9896(199907)188:3<237::AID-PATH343>3.0.CO;2-8. View

Shang Y, Hu X, DiRenzo J, Lazar M, Brown M . Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2001; 103(6):843-52. DOI: 10.1016/s0092-8674(00)00188-4. View

Osborne C, Bardou V, Hopp T, Chamness G, Hilsenbeck S, Fuqua S . Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003; 95(5):353-61. DOI: 10.1093/jnci/95.5.353. View

Song R, Barnes C, Zhang Z, Bao Y, Kumar R, Santen R . The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A. 2004; 101(7):2076-81. PMC: 357054. DOI: 10.1073/pnas.0308334100. View

Arpino G, Green S, Allred D, Lew D, Martino S, Osborne C . HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004; 10(17):5670-6. DOI: 10.1158/1078-0432.CCR-04-0110. View

Tomlins S, Rhodes D, Perner S, Dhanasekaran S, Mehra R, Sun X . Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310(5748):644-8. DOI: 10.1126/science.1117679. View

Ju B, Lunyak V, Perissi V, Garcia-Bassets I, Rose D, Glass C . A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science. 2006; 312(5781):1798-802. DOI: 10.1126/science.1127196. View

Carroll J, Meyer C, Song J, Li W, Geistlinger T, Eeckhoute J . Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006; 38(11):1289-97. DOI: 10.1038/ng1901. View

10.

Dowsett M, Smith I, Ebbs S, Dixon J, Skene A, AHern R . Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007; 99(2):167-70. DOI: 10.1093/jnci/djk020. View

11.

Fan P, Wang J, Santen R, Yue W . Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res. 2007; 67(3):1352-60. DOI: 10.1158/0008-5472.CAN-06-1020. View

12.

Holst F, Stahl P, Ruiz C, Hellwinkel O, Jehan Z, Wendland M . Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007; 39(5):655-60. DOI: 10.1038/ng2006. View

13.

Brown L, Hoog J, Chin S, Tao Y, Zayed A, Chin K . ESR1 gene amplification in breast cancer: a common phenomenon?. Nat Genet. 2008; 40(7):806-7. PMC: 2846830. DOI: 10.1038/ng0708-806. View

14.

Horlings H, Bergamaschi A, Nordgard S, Kim Y, Han W, Noh D . ESR1 gene amplification in breast cancer: a common phenomenon?. Nat Genet. 2008; 40(7):807-8. DOI: 10.1038/ng0708-807. View

15.

Reis-Filho J, Drury S, Lambros M, Marchio C, Johnson N, Natrajan R . ESR1 gene amplification in breast cancer: a common phenomenon?. Nat Genet. 2008; 40(7):809-10. DOI: 10.1038/ng0708-809b. View

16.

Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O . ESR1 gene amplification in breast cancer: a common phenomenon?. Nat Genet. 2008; 40(7):809. DOI: 10.1038/ng0708-809a. View

17.

Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y . Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci. 2009; 100(6):1012-7. PMC: 11159263. DOI: 10.1111/j.1349-7006.2009.01145.x. View

18.

Borg A, Tandon A, Sigurdsson H, Clark G, Ferno M, Fuqua S . HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990; 50(14):4332-7. View

19.

Mani R, Tomlins S, Callahan K, Ghosh A, Nyati M, Varambally S . Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009; 326(5957):1230. PMC: 2935583. DOI: 10.1126/science.1178124. View

20.

BURKHARDT L, Grob T, Hermann I, Burandt E, Choschzick M, Janicke F . Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2009; 123(3):757-65. DOI: 10.1007/s10549-009-0675-8. View